| Authors: |
Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahipal A; Department of Oncology, Mayo Clinic, Rochester, MN, USA.; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Javle M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang J; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Bauer TM; Sarah Cannon Research Institute, Nashville, TN, USA., Bajor DL; Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Elias AD; Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA., Shields A; Department of Hematology-Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Davis E; Department of Medicine, Vanderbilt University, Nashville, TN, USA., Chawla S; Sarcoma Oncology Research Center, Santa Monica, CA, USA., Safran H; Department of Medicine, Division of Hematology/Oncology, Lifespan Cancer Institute, Providence, RI, USA., Powderly JD; Cancer Therapy and Research Center, Carolina BioOncology Institute, Huntersville, NC, USA., D'Amato G; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Meyer CF; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Tang X; TopAlliance Biosciences Inc. Rockville, MD, USA., Yao S; TopAlliance Biosciences Inc. Rockville, MD, USA., Keegan P; TopAlliance Biosciences Inc. Rockville, MD, USA. |
